Explore 3 Stock Ideas & Industry Insights Download Free Report

News

U.S. Pre-Market Briefing: What U.S. Markets Face on Wednesday, May 6

With AMD and Arista both beating expectations after Tuesday's close, markets open Wednesday in a risk-on posture, but the ADP employment print at 8:15 a.m. ET will test whether the labour market is holding ahead of Friday's nonfarm payrolls. Walt Disney and AppLovin report …

Nitish Kishor | 05 May 2026

US Sector Performance Analysis: Tech Reasserts Dominance as Cyclicals Catch a Bid

The US equity market session on May 5, 2026, was characterized by a powerful "risk-on" rally led squarely by the Technology sector. Unlike recent sessions defined by defensive rotations and hard-asset inflation hedges, capital flowed back into historical growth engines and beaten-down cyclical value. …

Robert Luong | 05 May 2026

US Sector Momentum Analysis: Structural Shifts Continue Beneath the Tech Rally

The US equity market session on May 5, 2026, presented a textbook example of the divergence between absolute price action and relative momentum. While the daily tape was dominated by a massive "risk-on" rally led by Information Technology, the Relative Rotation Graph (RRG) paints …

Robert Luong | 05 May 2026

Edgewise Therapeutics (EWTX) Surges 21% as Insider Sale Masks Underlying Clinical Momentum

On the surface, the most newsworthy item surrounding Edgewise Therapeutics on Tuesday was a significant insider sale. Chief Medical Officer Joanne M. Donovan disclosed the sale of 55,230 shares across two transactions — 5,230 shares at $31.29 on May 4 and a much larger …

Nitish Kishor | 05 May 2026

Fate Therapeutics (FATE) Jumps 31% as FDA CDRP Selection Validates iPSC Cell Therapy Manufacturing Path

To appreciate why Fate Therapeutics shares surged 31% to $2.36 on Tuesday, it is necessary to understand what the FDA's CMC Development and Readiness Pilot Program actually represents — and why selection is a far more meaningful event than its understated name suggests.

Nitish Kishor | 05 May 2026

Biodesix (BDSX) Surges 33% After Blowout Q1 Results and Raised FY2026 Guidance

Biodesix delivered a first-quarter 2026 earnings report that, by any measure, represents a genuine commercial inflection for the lung diagnostics company. Revenue of $25.6 million grew 42% year over year — a growth rate that is exceptional for a commercial-stage diagnostics business and reflects …

Nitish Kishor | 05 May 2026

Rhythm Pharmaceuticals' EMANATE Trial Misses Primary Endpoints — What It Means for Setmelanotide's Expanding Ambitions

To understand why the EMANATE miss matters — and why it doesn't necessarily spell the end of the road — you need to understand what Setmelanotide is and what Rhythm has been trying to build with it.

Nitish Kishor | 05 May 2026

Three Semiconductor Stocks to Watch in May 2026: GSIT, VLN & BZAI

Trend Structure: Transition from Consolidation to UptrendGSIT is shifting from a prolonged consolidation phase into a potential uptrend.Key observations include:• Prior distribution phase between 6–10 has stabilized• Formation of higher lows since February• Early signs of trend reversal emerging

Nitish Kishor | 05 May 2026

Is Netflix Stock (NFLX) Heading Lower? Channel Rejection & RSI Signal More Downside

Netflix's daily chart presents a textbook bearish technical setup at a critical juncture. Following a 3.44% decline to close at 88'0, the stock is now trading below all four key exponential moving averages — the 20 (94'0), 50 (94'2), 100 (95'5), and 200 (98'5) …

Nitish Kishor | 05 May 2026

Gold Surges to $4,570 as Middle East Tensions Rattle Markets and Reshape Rate Expectations

Gold prices climbed sharply to $4,570 per ounce on Tuesday, staging a strong rebound after hitting a more than one-month low in the previous session, as investors sought refuge in the precious metal amid a rapidly deteriorating security situation in the Middle East. The …

Nitish Kishor | 05 May 2026
Support

Hi! How can we help you today?

Loading…